| Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing (NCT02906852) | Inivata | 2016-08-01 |
| EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism (NCT02859077) | Shanghai Pulmonary Hospital, Shanghai, China | 2016-08-01 |
| Proton Therapy to Reduce Acute Normal Tissue Toxicity in Locally Advanced Non-small-cell Lung Cancer (NCT02731001) | Technische Universität Dresden | 2016-08-01 |
| Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer (NCT04977791) | Shanghai Chest Hospital | 2016-07-21 |
| Parametric Imaging in Positron Emission Tomography for Patient With Lung Cancer (NCT02821936) | Centre Henri Becquerel | 2016-07-13 |
| A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NCT02754882) | Samsung Bioepis Co., Ltd. | 2016-07-05 |
| Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC) (NCT02419170) | Washington University School of Medicine | 2016-07-01 |
| Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer. (NCT02968979) | Chugai Pharma France | 2016-07-01 |
| A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) (NCT02576665) | Tocagen Inc. | 2016-07-01 |
| Risk Factors of Medistinal Metastasis in Endoscopic Staging of Lung Cancer (NCT02991924) | National Cancer Center, Korea | 2016-07-01 |
| Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers (NCT02838836) | University of Missouri-Columbia | 2016-07-01 |
| Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow (NCT03551951) | University of Missouri-Columbia | 2016-07-01 |
| A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors (NCT02886897) | Sun Yat-sen University | 2016-07-01 |
| Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers (NCT02803203) | Memorial Sloan Kettering Cancer Center | 2016-06-29 |
| Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS) (NCT02679170) | Pfizer | 2016-06-29 |
| A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) (NCT02775435) | Merck Sharp & Dohme LLC | 2016-06-09 |
| eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients (NCT02767804) | Xcovery Holdings, Inc. | 2016-06-01 |
| Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer (NCT02770014) | Dana-Farber Cancer Institute | 2016-06-01 |
| A Randomized Phase III Study of Palliative Radiation of Advanced Central Tumors With Intentional Avoidance of the Esophagus (NCT02752126) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2016-06-01 |
| First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation (NCT02883543) | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 2016-06-01 |
| Acquired Resistant Mechanism of the First-generation EGFR TKIs (NCT02804217) | Zhejiang Cancer Hospital | 2016-06-01 |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants (NCT02737501) | Ariad Pharmaceuticals | 2016-05-26 |
| Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (NCT02609776) | Janssen Research & Development, LLC | 2016-05-24 |
| GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients (NCT02575404) | Providence Health & Services | 2016-05-16 |
| Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer (NCT03746262) | Wake Forest University Health Sciences | 2016-05-13 |
| Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy (NCT03042221) | University of Colorado, Denver | 2016-05-10 |
| Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer (NCT02716311) | Intergroupe Francophone de Cancerologie Thoracique | 2016-05-01 |
| Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy (NCT02788461) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2016-05-01 |
| Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC) (NCT02681549) | Yale University | 2016-05-01 |
| Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer (NCT02780778) | Tianjin Medical University Cancer Institute and Hospital | 2016-05-01 |
| Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) (NCT02705339) | Washington University School of Medicine | 2016-05-01 |
| A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) (NCT02657434) | Hoffmann-La Roche | 2016-04-30 |
| An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread (NCT02658890) | Bristol-Myers Squibb | 2016-04-14 |
| Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols (NCT02682667) | National Cancer Institute (NCI) | 2016-04-11 |
| Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects (NCT03289780) | Biodesix, Inc. | 2016-04-04 |
| Immune Boost In Non-Small Cell Lung Cancer (NCT02319408) | University Hospital Heidelberg | 2016-04-01 |
| First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001 (NCT02896231) | Beijing Pearl Biotechnology Limited Liability Company | 2016-04-01 |
| Detection Cell Free DNA in Lung Cancer Patients (NCT02738593) | Sun Yat-sen University | 2016-04-01 |
| Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure (NCT02725918) | Guangdong Association of Clinical Trials | 2016-04-01 |
| uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung (NCT02755675) | Rigshospitalet, Denmark | 2016-04-01 |
| Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) (NCT02638090) | H. Lee Moffitt Cancer Center and Research Institute | 2016-03-22 |
| Alvopem® (Pemetrexed) Safety Assessment (NCT04843007) | NanoAlvand | 2016-03-15 |
| Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer (NCT02695550) | Centaurus Biopharma Co., Ltd. | 2016-03-01 |
| High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases (NCT02726568) | Betta Pharmaceuticals Co., Ltd. | 2016-03-01 |
| A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer (NCT02734524) | Southwest Hospital, China | 2016-03-01 |
| Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC (NCT02591615) | Alliance Foundation Trials, LLC. | 2016-03-01 |
| The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer (NCT02733107) | Third Military Medical University | 2016-03-01 |
| Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies (NCT02648724) | Symphogen A/S | 2016-03-01 |
| A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC (NCT02630186) | Clovis Oncology, Inc. | 2016-02-24 |
| A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies (NCT02572687) | Eli Lilly and Company | 2016-02-19 |
| Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NCT02659059) | Bristol-Myers Squibb | 2016-02-15 |
| OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure (NCT02654587) | OSE Immunotherapeutics | 2016-02-12 |
| Noninvasive vs. Invasive Lung Evaluation (NCT03615443) | Guardant Health, Inc. | 2016-02-12 |
| Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer (NCT02679963) | Gustave Roussy, Cancer Campus, Grand Paris | 2016-02-05 |
| Powered Vascular Stapler in Video-Assisted Thoracoscopic (VAT) Lobectomies (NCT02702921) | Ethicon Endo-Surgery | 2016-02-01 |
| D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC) (NCT02651441) | Shenzhen Hornetcorn Bio-technology Company, LTD | 2016-02-01 |
| Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease (NCT02469701) | howard safran | 2016-02-01 |
| Use of EBUS TBNA for Cell Culture as an Aid to Diagnose Lung Cancer and Lymphoma (NCT02710565) | Mid and South Essex NHS Foundation Trust | 2016-02-01 |
| Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria (NCT02619929) | Pierre Fabre Pharma GmbH | 2016-02-01 |
| Suction on Post-Operative Chest Tubes (NCT02911259) | Rigshospitalet, Denmark | 2016-02-01 |
| MPDL3280A With Chemoradiation for Lung Cancer (NCT02525757) | M.D. Anderson Cancer Center | 2016-01-26 |
| ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer (NCT02523469) | Medical University of South Carolina | 2016-01-08 |
| EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment (NCT02644889) | GenoSaber | 2016-01-01 |
| Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer. (NCT02470065) | European Organisation for Research and Treatment of Cancer - EORTC | 2016-01-01 |
| Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer (NCT02014545) | Wake Forest University Health Sciences | 2016-01-01 |
| Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method) (NCT02661009) | GenoSaber | 2016-01-01 |
| A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC (NCT02852083) | University Hospital Regensburg | 2016-01-01 |
| Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer (NCT02460367) | NewLink Genetics Corporation | 2016-01-01 |
| Surgical Treatment of Elderly Patients With cT1N0M0 Non-small Cell Lung Cancer Comparison Between Sublobar Resection and Lobectomy (NCT02360761) | Peking University People's Hospital | 2016-01-01 |
| Cellular Immunotherapy Synergize Chemotherapy in Patients With Stage IV NSCLC (NCT02669719) | Shanghai Chest Hospital | 2016-01-01 |
| Robotic Lobectomy vs. Thoracoscopic Lobectomy for Early Stage Lung Cancer: RCT (NCT02617186) | St. Joseph's Healthcare Hamilton | 2016-01-01 |
| Multicentric Analysis of Predictors of N1 Upstaging After Resection of cStage-I NSCLC (NCT02730897) | University Hospital, Gasthuisberg | 2016-01-01 |
| Abscopal Effect for Metastatic Non-small Cell Lung Cancer. (NCT02542930) | Zhejiang Provincial People's Hospital | 2016-01-01 |
| Uncommon EGFR AZD9291 (NCT03424759) | Samsung Medical Center | 2016-01-01 |
| Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer (NCT01951469) | Sun Yat-sen University | 2016-01-01 |
| The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine Kinase (NCT02755337) | Dr. Soetomo General Hospital | 2016-01-01 |
| Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) (NCT02584634) | Pfizer | 2015-12-18 |
| Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer (NCT02613507) | Bristol-Myers Squibb | 2015-12-11 |
| Evaluate EGFR Mutation Status and Impact Factors in North China (NCT02620657) | ying cheng | 2015-12-01 |
| Time Trends in Waiting Times of NSCLC Patients. (NCT01946490) | Maastricht Radiation Oncology | 2015-12-01 |
| Stereotactic Body Radiation Therapy for Un-biopsied Early- Stage Non Small Cell Lung Cancer (NCT02950337) | Loyola University | 2015-12-01 |
| ImmuniCell® in Patients With Advanced Cancers (NCT02459067) | TC Biopharm | 2015-12-01 |
| Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment (NCT02646020) | Sun Yat-sen University | 2015-12-01 |
| Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors (NCT02537561) | Washington University School of Medicine | 2015-12-01 |
| Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (NCT02504489) | BeyondSpring Pharmaceuticals Inc. | 2015-12-01 |
| Multiple-portal VATS Versus Uniportal VATS Lobectomy for Non-small Cell Lung Cancer (NCT02462356) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2015-12-01 |
| A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT02574078) | Bristol-Myers Squibb | 2015-11-23 |
| Long-term Epidemiological Follow-up of Non-small Cell Lung Cancer in Scandinavia (NCT02839629) | Bristol-Myers Squibb | 2015-11-23 |
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (NCT02568267) | Hoffmann-La Roche | 2015-11-19 |
| Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC (NCT02473133) | Centre Henri Becquerel | 2015-11-12 |
| Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) (NCT02504372) | Merck Sharp & Dohme LLC | 2015-11-06 |
| Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib (NCT02604342) | Hoffmann-La Roche | 2015-11-03 |
| Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body RadioTherapy and REsection (NCT02433574) | Juravinski Cancer Center | 2015-11-01 |
| Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor (NCT02562963) | Minghui Zhang | 2015-11-01 |
| Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases (NCT02616393) | Kadmon Corporation, LLC | 2015-11-01 |
| A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (NCT02498665) | Sumitomo Pharma America, Inc. | 2015-11-01 |
| MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC (NCT02592577) | Adaptimmune | 2015-11-01 |
| Intensity-modulated Radiotherapy (IMRT) With Simultaneous Integrated Boost (SIB) for Inoperable Non-small-cell Lung Cancer (NCT02841228) | Hunan Province Tumor Hospital | 2015-11-01 |
| Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] (NCT02486718) | Hoffmann-La Roche | 2015-10-31 |
| Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer (NCT02643407) | Guangdong Association of Clinical Trials | 2015-10-01 |